9月24日,CDE官网显示,复星医药旗下复星凯瑞的布瑞基奥仑赛注射液申报上市,推测适应症为复发/难治性前体B细胞急性淋巴细胞白血病成人患者。布瑞基奥仑赛是吉利德科学旗下Kite Pharma开发的靶向CD19的CAR-T细胞疗法,已在美国、欧盟等地获批上市。复星凯瑞拥有该药在中国内地、香港、澳门地区的权益,并正在开展相关单臂Ⅱ期临床。今年6月,复星凯瑞公布了该药在中国R/R B-ALL患者中的桥接...
Source Link9月24日,CDE官网显示,复星医药旗下复星凯瑞的布瑞基奥仑赛注射液申报上市,推测适应症为复发/难治性前体B细胞急性淋巴细胞白血病成人患者。布瑞基奥仑赛是吉利德科学旗下Kite Pharma开发的靶向CD19的CAR-T细胞疗法,已在美国、欧盟等地获批上市。复星凯瑞拥有该药在中国内地、香港、澳门地区的权益,并正在开展相关单臂Ⅱ期临床。今年6月,复星凯瑞公布了该药在中国R/R B-ALL患者中的桥接...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.